Radiopharm Theranostics
RADX
4 hedge funds and large institutions have $1.94M invested in Radiopharm Theranostics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.23M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$1.03M |
| 3 |
RP
Regal Partners
Sydney, NSW,
Australia
|
+$598K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.66K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Silverarc Capital Management
Boston,
Massachusetts
| $841K | +$1.23M | +187,406 | New |
|
|
AAA
2
Affinity Asset Advisors
New York
| $684K | +$1.03M | +156,171 | New |
|
|
RP
3
Regal Partners
Sydney, NSW,
Australia
| $408K | +$598K | +90,909 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $5.91K | +$8.66K | +1,317 | New |
|
RADX Hedge Fund Activity: Q4 2024 in Review
4 of the 7,597 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q4 2024, worth a combined $1.94M.
Buyers outnumbered sellers: 4 funds opened new RADX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $1.23M.
- 4 institutional investors held Radiopharm Theranostics (RADX) as of Q4 2024, up from 0 in Q3 2024.
- Funds reported $1.94M of Radiopharm Theranostics stock for Q4 2024.
- 4 funds opened new Radiopharm Theranostics positions in Q4 2024 and 0 closed out, a net change of +4 holders.
- The largest Radiopharm Theranostics buyer in Q4 2024 was Silverarc Capital Management, an estimated $1.23M added.
Based on aggregated 13F filings for Q4 2024.